Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 32 | 2024 | 8863 | 2.340 |
Why?
|
Glioma | 17 | 2023 | 3401 | 1.980 |
Why?
|
Glioblastoma | 13 | 2024 | 3481 | 1.130 |
Why?
|
Isocitrate Dehydrogenase | 11 | 2023 | 871 | 0.970 |
Why?
|
Oligodendroglioma | 3 | 2020 | 279 | 0.810 |
Why?
|
Myositis | 3 | 2019 | 251 | 0.770 |
Why?
|
Astrocytoma | 4 | 2023 | 790 | 0.760 |
Why?
|
Ganglioglioma | 2 | 2021 | 42 | 0.700 |
Why?
|
Multiple Acyl Coenzyme A Dehydrogenase Deficiency | 1 | 2018 | 8 | 0.660 |
Why?
|
Azacitidine | 1 | 2020 | 347 | 0.650 |
Why?
|
Azetidines | 2 | 2021 | 142 | 0.640 |
Why?
|
Riboflavin | 1 | 2018 | 108 | 0.630 |
Why?
|
Drug Resistance, Bacterial | 3 | 2021 | 1035 | 0.610 |
Why?
|
Molecular Targeted Therapy | 6 | 2023 | 2727 | 0.610 |
Why?
|
Mutation | 16 | 2024 | 29786 | 0.590 |
Why?
|
Hospital Costs | 2 | 2021 | 985 | 0.550 |
Why?
|
Lymphoma | 2 | 2022 | 1877 | 0.520 |
Why?
|
Aftercare | 1 | 2021 | 866 | 0.500 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2015 | 185 | 0.490 |
Why?
|
Hormone Antagonists | 1 | 2014 | 108 | 0.480 |
Why?
|
NAD | 1 | 2018 | 593 | 0.480 |
Why?
|
Bacterial Infections | 2 | 2019 | 1401 | 0.470 |
Why?
|
Antineoplastic Agents | 10 | 2023 | 13695 | 0.460 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 290 | 0.460 |
Why?
|
Corpus Callosum | 1 | 2018 | 737 | 0.460 |
Why?
|
Mifepristone | 1 | 2014 | 150 | 0.460 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2018 | 1157 | 0.440 |
Why?
|
Proto-Oncogene Proteins B-raf | 7 | 2023 | 2043 | 0.440 |
Why?
|
Neoplasms, Experimental | 1 | 2018 | 1276 | 0.430 |
Why?
|
Immunotherapy | 2 | 2017 | 4445 | 0.410 |
Why?
|
Genetic Heterogeneity | 1 | 2015 | 733 | 0.390 |
Why?
|
Piperidines | 2 | 2021 | 1602 | 0.390 |
Why?
|
Myocarditis | 1 | 2018 | 771 | 0.380 |
Why?
|
Medical Oncology | 1 | 2021 | 2265 | 0.360 |
Why?
|
Stereotaxic Techniques | 2 | 2022 | 536 | 0.350 |
Why?
|
Receptors, Progesterone | 1 | 2014 | 1097 | 0.350 |
Why?
|
DNA Mismatch Repair | 3 | 2023 | 426 | 0.340 |
Why?
|
Length of Stay | 2 | 2021 | 6309 | 0.340 |
Why?
|
Brain Diseases | 1 | 2018 | 1563 | 0.330 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2023 | 379 | 0.330 |
Why?
|
DNA Repair | 1 | 2018 | 2046 | 0.320 |
Why?
|
Immunologic Factors | 1 | 2017 | 1580 | 0.320 |
Why?
|
Patient Discharge | 1 | 2021 | 3313 | 0.310 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 7181 | 0.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11524 | 0.300 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2021 | 627 | 0.290 |
Why?
|
Cytokines | 2 | 2018 | 7322 | 0.280 |
Why?
|
France | 4 | 2021 | 517 | 0.280 |
Why?
|
Evolution, Molecular | 1 | 2015 | 1940 | 0.270 |
Why?
|
Meningioma | 1 | 2014 | 1209 | 0.260 |
Why?
|
Neoplasms | 4 | 2018 | 21683 | 0.260 |
Why?
|
Meningeal Neoplasms | 1 | 2014 | 1241 | 0.250 |
Why?
|
Humans | 66 | 2024 | 744343 | 0.250 |
Why?
|
Hospitalization | 4 | 2021 | 10262 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5535 | 0.240 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5172 | 0.230 |
Why?
|
Carcinoma, Renal Cell | 2 | 2017 | 3143 | 0.230 |
Why?
|
Phenotype | 3 | 2023 | 16365 | 0.220 |
Why?
|
Myelitis | 1 | 2022 | 53 | 0.210 |
Why?
|
Kidney Neoplasms | 2 | 2017 | 4262 | 0.200 |
Why?
|
Single-Cell Analysis | 3 | 2022 | 2183 | 0.200 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2023 | 250 | 0.200 |
Why?
|
Microsatellite Instability | 2 | 2023 | 684 | 0.200 |
Why?
|
Lomustine | 1 | 2020 | 59 | 0.190 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2022 | 134 | 0.190 |
Why?
|
Histiocytosis, Sinus | 1 | 2021 | 47 | 0.190 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2023 | 241 | 0.190 |
Why?
|
Optic Neuritis | 1 | 2022 | 166 | 0.190 |
Why?
|
Glutarates | 2 | 2022 | 236 | 0.180 |
Why?
|
Brain Stem Neoplasms | 1 | 2022 | 204 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9239 | 0.180 |
Why?
|
Neocortex | 1 | 2023 | 400 | 0.180 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 2023 | 403 | 0.170 |
Why?
|
Epilepsies, Partial | 1 | 2023 | 436 | 0.170 |
Why?
|
Cell Size | 1 | 2021 | 643 | 0.170 |
Why?
|
Central Nervous System | 3 | 2022 | 1357 | 0.170 |
Why?
|
Adult | 27 | 2024 | 214055 | 0.170 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2019 | 45 | 0.170 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5221 | 0.170 |
Why?
|
Encephalitis | 1 | 2022 | 423 | 0.170 |
Why?
|
Bacteria | 2 | 2021 | 2114 | 0.170 |
Why?
|
Vincristine | 1 | 2020 | 1039 | 0.160 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 648 | 0.160 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2019 | 130 | 0.160 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9274 | 0.160 |
Why?
|
Aneuploidy | 1 | 2021 | 530 | 0.160 |
Why?
|
Receptors, Somatostatin | 1 | 2018 | 129 | 0.150 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 86 | 0.150 |
Why?
|
Microsatellite Repeats | 1 | 2020 | 802 | 0.150 |
Why?
|
Receptors, Cholinergic | 1 | 2018 | 238 | 0.150 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 367 | 0.140 |
Why?
|
Glycine | 1 | 2020 | 671 | 0.140 |
Why?
|
Creatine Kinase | 1 | 2018 | 694 | 0.140 |
Why?
|
Retrospective Studies | 13 | 2023 | 77449 | 0.140 |
Why?
|
Deltoid Muscle | 1 | 2016 | 18 | 0.140 |
Why?
|
Mesencephalon | 1 | 2018 | 329 | 0.140 |
Why?
|
Biopsy | 3 | 2022 | 6756 | 0.140 |
Why?
|
Mutagenesis | 1 | 2020 | 1266 | 0.140 |
Why?
|
Meningitis | 1 | 2017 | 216 | 0.130 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2018 | 658 | 0.130 |
Why?
|
Signal Transduction | 2 | 2017 | 23403 | 0.130 |
Why?
|
Morpholines | 1 | 2019 | 571 | 0.130 |
Why?
|
Central Nervous System Neoplasms | 1 | 2023 | 895 | 0.130 |
Why?
|
Aminopyridines | 1 | 2019 | 542 | 0.130 |
Why?
|
Endonucleases | 1 | 2018 | 380 | 0.130 |
Why?
|
Male | 22 | 2021 | 350118 | 0.130 |
Why?
|
Urinary Tract Infections | 1 | 2021 | 788 | 0.130 |
Why?
|
Radiculopathy | 1 | 2017 | 197 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2023 | 1660 | 0.130 |
Why?
|
Clinical Trials as Topic | 4 | 2022 | 7913 | 0.130 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2020 | 3557 | 0.120 |
Why?
|
Lung Neoplasms | 2 | 2018 | 13102 | 0.120 |
Why?
|
Middle Aged | 19 | 2023 | 213383 | 0.120 |
Why?
|
Mice, Nude | 2 | 2018 | 3689 | 0.120 |
Why?
|
Rectal Neoplasms | 1 | 2023 | 1206 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2023 | 2455 | 0.120 |
Why?
|
Optic Nerve Diseases | 1 | 2017 | 327 | 0.120 |
Why?
|
Muscle, Skeletal | 2 | 2019 | 4931 | 0.110 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1401 | 0.110 |
Why?
|
Electromyography | 1 | 2018 | 1379 | 0.110 |
Why?
|
Aged | 16 | 2021 | 163280 | 0.110 |
Why?
|
Gene Frequency | 1 | 2020 | 3588 | 0.110 |
Why?
|
Quinoxalines | 1 | 2015 | 290 | 0.110 |
Why?
|
Bile Duct Neoplasms | 1 | 2018 | 567 | 0.110 |
Why?
|
Cholangiocarcinoma | 1 | 2018 | 516 | 0.110 |
Why?
|
Colorectal Neoplasms | 2 | 2023 | 6773 | 0.110 |
Why?
|
Pyridines | 2 | 2023 | 2825 | 0.100 |
Why?
|
RNA, Viral | 1 | 2021 | 2902 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2022 | 3597 | 0.100 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2018 | 828 | 0.100 |
Why?
|
Aged, 80 and over | 8 | 2021 | 57776 | 0.100 |
Why?
|
Europe | 1 | 2018 | 3339 | 0.100 |
Why?
|
Female | 22 | 2021 | 380194 | 0.100 |
Why?
|
Colonic Neoplasms | 1 | 2023 | 2541 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2022 | 1622 | 0.100 |
Why?
|
Prognosis | 6 | 2023 | 29063 | 0.090 |
Why?
|
Karnofsky Performance Status | 2 | 2021 | 173 | 0.090 |
Why?
|
Autoantibodies | 1 | 2018 | 2035 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1758 | 0.090 |
Why?
|
DNA Modification Methylases | 2 | 2021 | 206 | 0.090 |
Why?
|
Critical Illness | 1 | 2022 | 2670 | 0.080 |
Why?
|
Insurance, Health | 1 | 2021 | 2494 | 0.080 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15076 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2020 | 4803 | 0.080 |
Why?
|
Biological Products | 1 | 2017 | 860 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2018 | 8428 | 0.080 |
Why?
|
DNA Repair Enzymes | 2 | 2021 | 349 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 2728 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2015 | 934 | 0.080 |
Why?
|
Epilepsy | 1 | 2023 | 3310 | 0.080 |
Why?
|
Inpatients | 1 | 2019 | 2518 | 0.080 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2015 | 859 | 0.070 |
Why?
|
Software | 1 | 2021 | 4443 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2133 | 0.070 |
Why?
|
Young Adult | 8 | 2020 | 56430 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2015 | 1581 | 0.070 |
Why?
|
Genome, Human | 1 | 2020 | 4420 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2022 | 63114 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 5 | 2023 | 35421 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
Myocardium | 1 | 2018 | 4776 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3610 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2021 | 21746 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2635 | 0.060 |
Why?
|
Mice | 4 | 2020 | 81183 | 0.060 |
Why?
|
Pyrazoles | 1 | 2015 | 1972 | 0.060 |
Why?
|
Animals | 5 | 2020 | 168757 | 0.060 |
Why?
|
Residual Volume | 1 | 2023 | 41 | 0.060 |
Why?
|
Dihydroxyphenylalanine | 1 | 2023 | 76 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2022 | 39050 | 0.060 |
Why?
|
Sclerosis | 1 | 2023 | 213 | 0.060 |
Why?
|
5'-Nucleotidase | 1 | 2022 | 160 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10180 | 0.050 |
Why?
|
raf Kinases | 1 | 2021 | 122 | 0.050 |
Why?
|
Enzyme Inhibitors | 2 | 2023 | 3798 | 0.050 |
Why?
|
Algorithms | 1 | 2021 | 13881 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2018 | 9648 | 0.050 |
Why?
|
Adolescent | 5 | 2019 | 85781 | 0.050 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2021 | 261 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2015 | 4371 | 0.040 |
Why?
|
Oximes | 1 | 2021 | 311 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2849 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2022 | 326 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2021 | 371 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 730 | 0.040 |
Why?
|
Random Allocation | 1 | 2023 | 2429 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2023 | 1526 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3752 | 0.040 |
Why?
|
Homozygote | 1 | 2023 | 1785 | 0.040 |
Why?
|
DNA Helicases | 1 | 2024 | 859 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19905 | 0.040 |
Why?
|
Central Nervous System Diseases | 1 | 2022 | 518 | 0.040 |
Why?
|
Isomerism | 1 | 2018 | 201 | 0.040 |
Why?
|
Prospective Studies | 4 | 2023 | 53288 | 0.040 |
Why?
|
DNA Polymerase II | 1 | 2018 | 107 | 0.040 |
Why?
|
DNA Mutational Analysis | 2 | 2018 | 4186 | 0.040 |
Why?
|
Melanoma | 1 | 2016 | 5510 | 0.040 |
Why?
|
Adenosine | 1 | 2022 | 825 | 0.040 |
Why?
|
Myositis, Inclusion Body | 1 | 2019 | 147 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2022 | 847 | 0.040 |
Why?
|
Genomics | 2 | 2024 | 5720 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2018 | 553 | 0.040 |
Why?
|
Pyridones | 1 | 2021 | 712 | 0.040 |
Why?
|
Brain | 3 | 2022 | 26385 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 40561 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 6538 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2018 | 644 | 0.030 |
Why?
|
DNA Methylation | 2 | 2021 | 4286 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
Documentation | 1 | 2021 | 871 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1788 | 0.030 |
Why?
|
Inflammation | 1 | 2015 | 10638 | 0.030 |
Why?
|
Imidazoles | 1 | 2021 | 1206 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 281 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2021 | 11366 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2015 | 105 | 0.030 |
Why?
|
Disease Progression | 2 | 2023 | 13284 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12788 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2019 | 1285 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2021 | 1783 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2015 | 323 | 0.030 |
Why?
|
Information Services | 1 | 2015 | 244 | 0.030 |
Why?
|
Histones | 1 | 2023 | 2599 | 0.030 |
Why?
|
Genome | 1 | 2021 | 1808 | 0.030 |
Why?
|
Internationality | 1 | 2018 | 1003 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2019 | 3701 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3462 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2015 | 629 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2886 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3760 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2022 | 5078 | 0.030 |
Why?
|
Necrosis | 1 | 2016 | 1643 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1637 | 0.030 |
Why?
|
Seizures | 1 | 2024 | 2859 | 0.020 |
Why?
|
Hippocampus | 1 | 2023 | 3675 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2569 | 0.020 |
Why?
|
Risk | 1 | 2023 | 9687 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2018 | 6314 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2023 | 4554 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2505 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3616 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
Equipment Design | 1 | 2018 | 3582 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3479 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3586 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 5867 | 0.020 |
Why?
|
Child | 3 | 2023 | 77709 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2015 | 1086 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4933 | 0.020 |
Why?
|
Risk Assessment | 2 | 2022 | 23338 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2024 | 5853 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2015 | 2879 | 0.020 |
Why?
|
International Cooperation | 1 | 2015 | 1420 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6895 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10943 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6234 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4751 | 0.020 |
Why?
|
Lipids | 1 | 2018 | 3305 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4851 | 0.020 |
Why?
|
Child, Preschool | 2 | 2019 | 41006 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 7729 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10252 | 0.020 |
Why?
|
Models, Biological | 1 | 2021 | 9583 | 0.020 |
Why?
|
Hospitals | 1 | 2019 | 3952 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12245 | 0.020 |
Why?
|
Cell Line | 1 | 2018 | 15997 | 0.010 |
Why?
|
Transcription Factors | 1 | 2024 | 12208 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11031 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2018 | 19229 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 20947 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 25625 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 40075 | 0.010 |
Why?
|
Infant | 1 | 2019 | 35136 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 72290 | 0.010 |
Why?
|